Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Vascularised and functional human liver from an iPSC-derived organ bud transplant

ABSTRACT: Vascularised and functional human liver from an iPSC-derived organ bud transplant

PROVIDER: PRJNA201333 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Vascularised and functional human liver from an iPSC-derived organ bud transplant

Project description:Critical shortage of donor organs for treating end-stage organ failure highlights the urgent need for generating organs from induced pluripotent stem cells (hiPSCs). Despite many reports describing functional cell differentiation, no studies have succeeded in generating a three-dimensional vascularised organ such as liver. Here, we show the generation of vascularised and functional human liver from hiPSCs by transplantation of liver buds created in vitro (hiPSC-LBs). Specified hepatic cells self-organised into three-dimensional hiPSC-LBs by recapitulating organogenetic interactions between endothelial and mesenchymal cells. Immunostaining and gene expression analyses revealed resemblance between in vitro grown hiPSC-LBs and in vivo liver buds. Human vasculatures in hiPSC-LB transplants became functional by connecting to the host vessels within 48 hours. The formation of functional vasculatures stimulated the maturation of hiPSC-LBs into tissue resembling the adult liver. Highly metabolic hiPSC-derived tissue performed liver-specific functions such as protein production and human-specific drug metabolism without recipient liver replacement. Comparison of liver developmental gene signatures among hiPSC-LB, hFLC-LB, human adult (30 years old) liver tissues (hALT) and mouse liver tissue (mLT) of various developmental stages (E9.5~P8weeks).

2013-07-01 | E-GEOD-46631 | biostudies-arrayexpress

Vascularised and functional human liver from an iPSC-derived organ bud transplant

2013-07-01 | GSE46631 | GEO

Human iPSC-liver organoid transplant reduces fibrosis by immunomodulation

Project description:Donor organ shortage for transplant is a serious problem worldwide. Organoid culture technology, which allows the generation of complex organs from stem cells, provides a potential solution. We previously reported in vivo vascularization of human induced pluripotent stem cell (hiPSC)-derived liver buds (LBs) and subsequent improved survival of recipient mice with acute liver failure1,2. Here, we show that mid-gestational fetal liver tissue can generate de novo liver when grafted onto the surface of host livers and improve survival and liver functions in a model of liver failure. Next, we created complex fetal liver-like organoids (LOs) by a fusion of hiPSC-LBs to induce static cell-cell interactions, and show that these contain hepatocytes, vasculature, and bile duct after transplantation. Fused hiPSC-LOs show superior liver functions compared to hiPSC-LBs and improve survival and functions of liver failure model upon transplantation. Finally, transplant of fused hiPSC-LOs ameliorates liver fibrosis, a symptom of liver cirrhosis which leads to organ dysfunction, through their immunomodulatory effects especially on macrophage polarization that plays an important role in the regulation of liver fibrosis3–5. Taken together, our results suggest that hiPSC-LO transplant could be a promising therapeutic option for liver failure patients in the near future

2025-09-30 | GSE214648 | GEO

Human iPSC-liver organoid transplant reduces fibrosis by immunomodulation

Project description:Human iPSC-liver organoid transplant reduces fibrosis by immunomodulation

| PRJNA886614 | ENA

The Gut Microbiome of liver transplant recipients Ã¢Â€Â“ Cross-sectional + Longitudinal (renal and liver)

Project description:TransplantLines is designed as a single-center, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. In the TransplantLines gut microbiome study the gut microbiome of solid organ transplant recipients is characterized and linked to clinical phenotypes. This batch contains the cross-sectional data from liver transplant recipients and longitudinal data from renal and liver transplant recipients.

| EGAS00001006258 | EGA

Gut microbiota associated with organ transplant outcome

Project description:Gut microbiota associated with organ transplant outcome Targeted loci environmental

| PRJNA480643 | ENA

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Project description:The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

| 2262897 | ecrin-mdr-crc

Assessment of ‘molecular organ age’ in pre-transplant kidney biopsies

Project description:Assessment of ‘molecular organ age’ in pre-transplant kidney biopsies

| PRJEB58682 | ENA

Assessment of ‘molecular organ age’ in pre-transplant kidney biopsies

Project description:Assessment of ‘molecular organ age’ in pre-transplant kidney biopsies

| PRJNA923683 | ENA

Multi-omics of Bladder Cancers of Solid Organ Transplant Recipients

Project description:Multi-omics of Bladder Cancers of Solid Organ Transplant Recipients

| PRJNA865854 | ENA